Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity
- 25 May 2006
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (21) , 2282-2284
- https://doi.org/10.1056/nejmcibr061878
Abstract
Gastrointestinal stromal tumors have been shown to respond to imatinib mesylate in a manner dependent on immune-cell function. A new type of immune cell that shares characteristics with both natural killer cells and dendritic cells seems to mediate this response.Keywords
This publication has 5 references indexed in Scilit:
- A novel dendritic cell subset involved in tumor immunosurveillanceNature Medicine, 2006
- Interferon-producing killer dendritic cells provide a link between innate and adaptive immunityNature Medicine, 2006
- Close encounters of different kinds: Dendritic cells and NK cells take centre stageNature Reviews Immunology, 2005
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effectsJournal of Clinical Investigation, 2004
- Rat Spleen Dendritic Cells Express Natural Killer Cell Receptor Protein 1 (NKR-P1) and Have Cytotoxic Activity to Select Targets via a Ca2+-dependent MechanismThe Journal of Experimental Medicine, 1997